All In Biotech

Drug Trial Radar · NCT07762287

Evaluation of Possible Ways the Body May Process Two Different Forms of Elinzanetant in Healthy Study Participants

A Combined Single- and Multiple-dose, Open-label, Randomized, 2 x 2 Crossover Study to Investigate the Relative Bioavailability of Two Oral Elinzanetant (BAY 3427080) Formulations in Healthy Female Participants

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Jul 22, 2026

Primary completion

Jan 22, 2027

Study completion Jan 22, 2027

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Aug 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is being done to compare two forms of the medicine elinzanetant, which is used to help manage hot flush symptoms related to changes in female hormones. The researchers want to find out whether a new tablet form of elinzanetant is absorbed and processed by the body of healthy women in a similar way than an existing capsule form. About 100 healthy women aged 18 to 65 will take part in this study. Each participant will receive both forms of the medicine at different times during the study. They will take the medicine once daily for several days under controlled conditions at a study center, and blood samples will be collected to measure how the body absorbs and handles the drug. The study is designed so that each participant can be compared to herself, helping researchers clearly understand any differences between the two formulations.

Conditions

  • Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women

Interventions

  • Elinzanetant (BAY 3427080) treatment ADrug

    Elinzanetant treatment A is administered orally once daily.

  • Elinzanetant (BAY 3427080) treatment BDrug

    Elinzanetant treatment B is administered orally once daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area Under the Plasma Concentration-Time Curve Over 24 Hours After Multiple Dosing (AUC(0-24)md)Time frame: On Day 11 of each 12-day treatment period (study intervention administered on Days 1-10)
  2. Maximum Observed Plasma Concentration After Multiple Dosing (Cmax,md)Time frame: On Day 11 of each 12-day treatment period (study intervention administered on Days 1-10)
  3. Minimum Observed Plasma Concentration During Dosing Interval After Multiple Dosing (Cmin,md)Time frame: On Day 11 of each 12-day treatment period (study intervention administered on Days 1-10)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Altasciences

    Mount Royal, Quebec, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.